Navigation Links
BIDMC scientist David J. Friedman, M.D., receives award from Doris Duke Charitable Foundation

BOSTON David J. Friedman, MD, a clinician and scientific investigator in the Division of Nephrology and Center for Vascular Biology Research at Beth Israel Deaconess Medical Center (BIDMC) has been selected to receive a Clinical Scientist Development Award (CSDA) from the Doris Duke Charitable Foundation. The three-year award, which totals $486,000, will support Friedman's research into the genetic and environmental factors that lead to kidney disease in African Americans, in particular the role of a gene called APOL1.

"As investigators, physician-scientists face a particularly large challenge: meeting both the demands of seeing patients and conducting research," said Betsy Myers, Director of the Medical Research Program for the Doris Duke Charitable Foundation. "Supporting the work of promising investigators while they're still early in their careers remains critical to keeping the clinical research workforce strong."

A graduate of Harvard College, Friedman received his medical degree from the Yale School of Medicine and went on to complete his residency at BIDMC. From 2003 to 2005 he was a Clinical Fellow in BIDMC's Division of Nephrology and from 2004 to 2007 was a Research Fellow in the Division of Nephrology. An Assistant Professor of Medicine at Harvard Medical School (HMS), Friedman is the recipient of numerous HMS teaching awards.

"Dr. Friedman's important work may one day translate into new diagnostic tools and therapeutic strategies to help prevent end-stage renal disease," explains BIDMC Chief of Nephrology Martin Pollak, MD. Last year Pollak and Friedman co-authored a paper in the journal Science that identified two common coding variants in the APOL1 gene on chromosome 22 which greatly increase the risk of end-stage renal disease in African Americans. "This devastating and costly condition affects nearly 500,000 people in the United States, and is four to five times more common in African Americans compared to Caucasian Americans. Clearly, new diagnostic and treatment options are needed," adds Pollak.

Furthermore, says Friedman, as many as 3.5 million African Americans likely have the high risk APOL1 genotype.

"This gene increases a person's risk of developing kidney failure approximately 10-fold," he explains. "Investigating this gene is particularly challenging because only humans and a few primate species have the APOL1 gene in their genomes. Studies in patients with the disease are essential, and with this support from the Doris Duke Charitable Foundation, we hope to develop a better understanding of the genetic and environmental influences that modify the major APOL1 risk alleles."


Contact: Bonnie Prescott
Beth Israel Deaconess Medical Center

Related biology news :

1. BIDMC scientist John Rinn, Ph.D., receives Damon-Runyon Rachleff Innovation Award
2. Cutting-edge imaging techniques for neuroscientists available in latest laboratory manual
3. New duck-billed dinosaur gives scientists clues to evolution of head ornamentation and provinciality
4. Scripps Research scientists create vaccine against heroin high
5. Hebrew U. scientists show for first time how early human embryo acquires its shape
6. Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call for social scientists to take their place at the HIV/AIDS policy-making table, and stress the need for a long-term response to AIDS
7. OHSU scientists discover new role for vitamin C in the eye -- and the brain
8. Scientists to assemble knowledgebase on plants, microbes, to aid US biofuel, environment efforts
9. BUSM professor selected as American Heart Association Distinguished Scientist
10. Simple little spud helps scientists crack potatos mighty genome
11. Scientists discover first gonorrhea strain resistant to all available antibiotics
Post Your Comments:
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, ... in the development and sale of broadly enabling, pressure ... life sciences industry, today announced it has received gross ... $5 million Private Placement (the "Offering"), increasing the total ...  One or more additional closings are expected in the ...
(Date:11/12/2015)...   Growing need for low-cost, easy to ... paving the way for use of biochemical sensors ... in clinical, agricultural, environmental, food and defense applications. ... medical applications, however, their adoption is increasing in ... emphasis on improving product quality and growing need ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... SUNNYVALE, Calif. , Nov. 24, 2015 ... executives will be speaking at the following conference, and ... New York, NY      Tuesday, December 1, ... New York, NY      Tuesday, December 1, ...      Piper Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... Florida (PRWEB) , ... November 24, 2015 , ... ... biggest event of the year and one of the premier annual events for ... and ran from 8–11 November 2015, where ISPE hosted the largest number of ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
Breaking Biology Technology: